Instrument Inactif

Communiqués Pain Therapeutics, Inc. Nasdaq

Actions

US69562K1007

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

29/07	Filana Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
07/05	Filana Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

29/07	Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update	GL
08/05	Filana Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Filana Therapeutics : Corporate Presentation May 2026	PU
07/05	Filana Therapeutics Reports Q1 2026 Financial Results and Business Update	GL
05/05	Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII	GL
05/05	Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII	AQ
15/04	Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data	GL
12/03	Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	GL
10/03	Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.	GL
10/03	Cassava Sciences : SAVA Corp 4Presentation rebrandas of Mar 09 2026	PU
19/02	Cassava Announces Closure of U.S. Department of Justice Investigation	GL
19/02	Cassava Announces Closure of U.S. Department of Justice Investigation	AQ
14/01	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's disease in the Journal of Prevention of Alzheimer's disease	AQ
13/01	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease	GL
13/01	Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease	AQ
24/12	HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS	PR
23/12	Cassava Announces Agreement to Settle Securities Class Action Litigation	GL
12/11	Cassava Reports Q3 2025 Financials Results and Provides Business Update	GL
12/11	Cassava Reports Q3 2025 Financials Results and Provides Business Update	AQ
22/10/25	Cassava Sciences Appoints Dawn C. Bir to the Board of Directors	GL
08/09/25	Cassava Sciences : SAVA Corp Presentation 090825	PU
25/08/25	Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference	GL
14/08/25	Cassava Reports Q2 2025 Financials Results and Provides Business Update	GL
11/08/25	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer	AQ
07/08/25	Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer	GL